High serum biotin concentrations in patients taking biotin supplements may cause an interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.

Gold serum separator (SST) tube

OR 

Red serum vial/tube - 5 mL

Immediately following collection, thoroughly mix sample by gently inverting 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection
3. Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
4. Freeze

Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp)

Lavender (EDTA), 4mL

Dark green heparin

Lavender/Dk green:

Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

Lavender/Dk green:

1. Spin within two (2) hours of sample collection
2. Transfer the plasma to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as the appropriate plasma type
3. Freeze

Frozen (preferred) - 14 days

Refrigerated  - 14 days

Ambient - 14 days

Freeze/thaw cylces - stable x6

• Gross hemolysis
• Gross lipemia

Electrochemiluminescence Immunoassay (ECLIA)

An interpretive report will be provided

In the absence of anti-vedolizumab antibodies, the Vedolizumab drug level reflects the total Vedolizumab concentration. In the presence of anti-vedolizumab antibodies, the Vedolizumab concentration reflects the antibody-unbound fraction of Vedolizumab.

The presence of Vedolizumab drug, even at concentrations well above target treatment levels does not interfere with anti-Vedolizumab antibody measurement. All positive anti-Vedolizumab antibody results are verified by a confirmatory test.